Periampullary pancreatic somatostatinoma

Michael House, Charles J. Yeo, Richard D. Schulick

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: Somatostatinomas involving the gastrointestinal tract are extremely rare neoplasms that typically present with indolent, nonspecific symptoms in the absence of systemic neuroendocrine manifestations that characterize the somatostatinoma syndrome. Because of a relatively large size at the time of presentation (average diameter of 5 cm) and common location within the head of the pancreas, the Whipple procedure (pancreaticoduodenectomy) serves as the predominant modality for curative and palliative surgical approaches. Methods: Two cases of somatostatinoma involving the minor duodenal papilla with concomitant pancreatic divisum were reviewed, with a general overview of this unique islet cell tumor. Results: Unlike typical somatostatinomas, these two tumors were subcentimeter in size but were associated with synchronous regional metastasis. Conclusions: Somatostatinomas are often associated with regional and/or portal metastases at the time of diagnosis, and only 60% to 70% of surgical cases result in complete tumor resection. Predictors of an unfavorable prognosis include size > 3 cm, poor cytological differentiation, regional and/or portal metastasis, and incomplete surgical resection. Even in the presence of synchronous metastases, the 5-year overall survival for patients with somatostatinoma is approximately 40%. Currently, there are no clinical trials demonstrating significant improvement in survival with the use of adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)869-874
Number of pages6
JournalAnnals of Surgical Oncology
Volume9
Issue number9
StatePublished - Nov 2002
Externally publishedYes

Fingerprint

Somatostatinoma
Neoplasm Metastasis
Islet Cell Adenoma
Neoplasms
Pancreaticoduodenectomy
Survival
Pancreatic Ducts
Gastrointestinal Tract
Pancreas
Clinical Trials

Keywords

  • Islet cell
  • Neuroendocrine
  • Pancreas
  • Pancreaticoduodenectomy
  • Somatostatinoma
  • Whipple procedure

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

House, M., Yeo, C. J., & Schulick, R. D. (2002). Periampullary pancreatic somatostatinoma. Annals of Surgical Oncology, 9(9), 869-874.

Periampullary pancreatic somatostatinoma. / House, Michael; Yeo, Charles J.; Schulick, Richard D.

In: Annals of Surgical Oncology, Vol. 9, No. 9, 11.2002, p. 869-874.

Research output: Contribution to journalArticle

House, M, Yeo, CJ & Schulick, RD 2002, 'Periampullary pancreatic somatostatinoma', Annals of Surgical Oncology, vol. 9, no. 9, pp. 869-874.
House, Michael ; Yeo, Charles J. ; Schulick, Richard D. / Periampullary pancreatic somatostatinoma. In: Annals of Surgical Oncology. 2002 ; Vol. 9, No. 9. pp. 869-874.
@article{bc8a15454ac64acdb8af81fa1606d39b,
title = "Periampullary pancreatic somatostatinoma",
abstract = "Background: Somatostatinomas involving the gastrointestinal tract are extremely rare neoplasms that typically present with indolent, nonspecific symptoms in the absence of systemic neuroendocrine manifestations that characterize the somatostatinoma syndrome. Because of a relatively large size at the time of presentation (average diameter of 5 cm) and common location within the head of the pancreas, the Whipple procedure (pancreaticoduodenectomy) serves as the predominant modality for curative and palliative surgical approaches. Methods: Two cases of somatostatinoma involving the minor duodenal papilla with concomitant pancreatic divisum were reviewed, with a general overview of this unique islet cell tumor. Results: Unlike typical somatostatinomas, these two tumors were subcentimeter in size but were associated with synchronous regional metastasis. Conclusions: Somatostatinomas are often associated with regional and/or portal metastases at the time of diagnosis, and only 60{\%} to 70{\%} of surgical cases result in complete tumor resection. Predictors of an unfavorable prognosis include size > 3 cm, poor cytological differentiation, regional and/or portal metastasis, and incomplete surgical resection. Even in the presence of synchronous metastases, the 5-year overall survival for patients with somatostatinoma is approximately 40{\%}. Currently, there are no clinical trials demonstrating significant improvement in survival with the use of adjuvant therapy.",
keywords = "Islet cell, Neuroendocrine, Pancreas, Pancreaticoduodenectomy, Somatostatinoma, Whipple procedure",
author = "Michael House and Yeo, {Charles J.} and Schulick, {Richard D.}",
year = "2002",
month = "11",
language = "English (US)",
volume = "9",
pages = "869--874",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Periampullary pancreatic somatostatinoma

AU - House, Michael

AU - Yeo, Charles J.

AU - Schulick, Richard D.

PY - 2002/11

Y1 - 2002/11

N2 - Background: Somatostatinomas involving the gastrointestinal tract are extremely rare neoplasms that typically present with indolent, nonspecific symptoms in the absence of systemic neuroendocrine manifestations that characterize the somatostatinoma syndrome. Because of a relatively large size at the time of presentation (average diameter of 5 cm) and common location within the head of the pancreas, the Whipple procedure (pancreaticoduodenectomy) serves as the predominant modality for curative and palliative surgical approaches. Methods: Two cases of somatostatinoma involving the minor duodenal papilla with concomitant pancreatic divisum were reviewed, with a general overview of this unique islet cell tumor. Results: Unlike typical somatostatinomas, these two tumors were subcentimeter in size but were associated with synchronous regional metastasis. Conclusions: Somatostatinomas are often associated with regional and/or portal metastases at the time of diagnosis, and only 60% to 70% of surgical cases result in complete tumor resection. Predictors of an unfavorable prognosis include size > 3 cm, poor cytological differentiation, regional and/or portal metastasis, and incomplete surgical resection. Even in the presence of synchronous metastases, the 5-year overall survival for patients with somatostatinoma is approximately 40%. Currently, there are no clinical trials demonstrating significant improvement in survival with the use of adjuvant therapy.

AB - Background: Somatostatinomas involving the gastrointestinal tract are extremely rare neoplasms that typically present with indolent, nonspecific symptoms in the absence of systemic neuroendocrine manifestations that characterize the somatostatinoma syndrome. Because of a relatively large size at the time of presentation (average diameter of 5 cm) and common location within the head of the pancreas, the Whipple procedure (pancreaticoduodenectomy) serves as the predominant modality for curative and palliative surgical approaches. Methods: Two cases of somatostatinoma involving the minor duodenal papilla with concomitant pancreatic divisum were reviewed, with a general overview of this unique islet cell tumor. Results: Unlike typical somatostatinomas, these two tumors were subcentimeter in size but were associated with synchronous regional metastasis. Conclusions: Somatostatinomas are often associated with regional and/or portal metastases at the time of diagnosis, and only 60% to 70% of surgical cases result in complete tumor resection. Predictors of an unfavorable prognosis include size > 3 cm, poor cytological differentiation, regional and/or portal metastasis, and incomplete surgical resection. Even in the presence of synchronous metastases, the 5-year overall survival for patients with somatostatinoma is approximately 40%. Currently, there are no clinical trials demonstrating significant improvement in survival with the use of adjuvant therapy.

KW - Islet cell

KW - Neuroendocrine

KW - Pancreas

KW - Pancreaticoduodenectomy

KW - Somatostatinoma

KW - Whipple procedure

UR - http://www.scopus.com/inward/record.url?scp=0036840792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036840792&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 869

EP - 874

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 9

ER -